Table: Aska Pharmaceutical Holdings - 9-MTH group results
07/02/2022 06:05
Feb 7 (Reuters)-
Aska Pharmaceutical Holdings Co., Ltd.
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
9 months ended 9 months ended Year to
Dec 31, 2021 Dec 31, 2020 Mar 31, 2022
LATEST YEAR-AGO LATEST
RESULTS RESULTS FORECAST
Sales 44.18 55.00
Operating 4.68 3.50
Recurring 4.79 3.60
Net 4.08 3.00
EPS 143.76 yen 105.67 yen
Ann Div 14.00 yen
-Q2 div 7.00 yen
-Q4 div 7.00 yen
NOTE - Aska Pharmaceutical Holdings Co., Ltd..
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4886.T
Recent news on ASKA Pharmaceutical Holdings
See all newsTable: Aska Pharmaceutical Holdings -Q1 group results
Brief: Dalton Investment Strongly Oppose Conditional Activation Of Countermeasures Announced By Aska Pharmaceutical Holdings On May 25
Brief: Aska Pharmaceutical -Plan To Put To Shareholders Proposal On Countermeasures Against Potential Large-Scale Share Purchase By Dalton And Related Parties
Table: Aska Pharmaceutical Holdings -2025/26 group results
Table: Aska Pharmaceutical Holdings -2025/26 group results